AbbVie Announced That The U.S. FDA Has Approved EPKINLY As The First And Only T-cell Engaging Bispecific Antibody Administered Subcutaneously For The Treatment Of Adults With Relapsed Or Refractory Follicular Lymphoma
Portfolio Pulse from Benzinga Newsdesk
AbbVie announced that the U.S. FDA has approved EPKINLY as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or refractory follicular lymphoma.
June 27, 2024 | 6:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie has received FDA approval for EPKINLY, a new treatment for relapsed or refractory follicular lymphoma. This approval marks a significant milestone as it is the first subcutaneous T-cell engaging bispecific antibody for this condition.
The FDA approval of EPKINLY is a significant milestone for AbbVie, as it introduces a novel treatment option for relapsed or refractory follicular lymphoma. This approval is likely to boost investor confidence and positively impact AbbVie's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100